{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '14', 'Statistics', 'A Statistical Analysis Plan (SAP) will be written as a separate document to be completed after', 'finalizing the protocol developed during the conduct of the study. The SAP will be finalized', 'prior to database closure.', 'Any changes to the statistical analyses planned in the protocol will be justified and documented', 'in the SAP if they were decided before database lock. Any changes made to the SAP after the', 'database lock will be documented in the final study report.', 'Summary statistics for continuous variables will include number (n), mean, standard deviation,', 'median, minimum first quartile, third quartile, and maximum.', 'Summary statistics for discrete variables will include frequencies and percentages.', 'If not otherwise specified, p-values will be presented as two-sided p-values and the level of', 'significance is set to 5% (two-sided).', 'The statistical analysis will be performed using the software SAS version 9.3 or higher.', 'Exploratory analyses (e.g. inflammatory markers) will not be part of statistical analyses and', 'will be analyzed outside of the study setting.', '14.1 Protocol Deviations', 'Deviations from the protocol including violations of inclusion / exclusion criteria will be', \"assessed as 'minor' or 'major' on a case by case basis in cooperation with the sponsor. This\", 'assessment will take place during a data review meeting, which will take place after the last', 'observation of the last patient and prior to database closure. Major deviations from the protocol', 'will lead to the exclusion of a patient from the per protocol set.', '14.2 Analysis Populations', 'The following two analysis sets are defined in this study:', 'Full Analysis Set (FAS)', 'The Full Analysis Set (FAS) is defined as all patients who received at least one dose of study', 'drug.', 'Per Protocol Set (PP)', 'The Per Protocol Set (PP) is defined as all patients who received at least one dose of study', 'drug who completed the study with no major protocol violations.', 'The definition of the PP set will be finalized in the data review meeting prior to database', 'closure.', 'The FAS and PP will be used for analyses of efficacy endpoints. Since the FAS consists of all', 'patients who received at least one dose of study drug, the FAS will additionally serve as safety', 'analysis set and will be used for analysis of safety endpoints.', 'Page 51 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '14.3 Demographics and Baseline Characteristics', 'The analyses of patient demographic data will be presented for the FAS and PP. Other', 'baseline characteristics including medical history will be based on the FAS.', 'Demographics and Baseline Characteristics', 'Summary statistics will be presented for demographic and baseline characteristic variables.', 'The number and percentage of patients in each category will be presented for categorical', 'variables.', 'Medical History', 'Frequency tables for medical history will present the number and percentage of patients per', 'Medical Dictionary for Regulatory Activities (MedDRA), system organ classes (SOC) and', 'preferred terms (PT).', '14.4 Treatments', 'Prior and Concomitant Medications', 'Frequency tables for prior and concomitant medications will present the number and', 'percentage of patients per Anatomic-Therapeutically-Chemical Code (ATC) class 2', '(therapeutic main group) and ATC class 3 (pharmacological sub-group).', 'Prior medications are defined as medications taken prior to first intake of study drug. Any', 'medication given at least once after the first intake of study drug will be considered as', 'concomitant medication. This means, a medication might be assigned to both, prior and', 'concomitant medications. If no unambiguous assignment to prior and concomitant medication', 'is possible due to incomplete or missing dates, the medication will be assigned to both, prior', 'and concomitant medications.', '14.5 Analysis of Primary Endpoint', '14.5.1 Primary Endpoint', 'The primary endpoint is the percentage change from baseline in PPPASI after 20 weeks of', 'treatment with apremilast, defined in 8.2.1.', '14.5.2 Statistical Methods of Analysis', 'The primary endpoint percent change from baseline in PPPASI after 20 weeks of treatment', 'will be summarized as continuous variable together with 95%-confidence limits. Statistical', 'comparison between post- versus pre-treatment values will be done based on the Wilcoxon', 'signed-rank test with two-sided p-value <0.05 indicating significance. Missing values will be', 'replaced using last-observation-carried-forward (LOCF) method for the analysis of the primary', 'endpoint based on the FAS.', 'The analysis of the primary endpoint will be repeated for the PP set, this analysis will be', 'considered as supportive.', 'Page 52 of 75']\n\n###\n\n", "completion": "END"}